Dr. Chengyuan Liang is a Professor at the School of Biological and Pharmaceutical Sciences, Shaanxi University of Science and Technology. He also serves as Director of the Xi’an Key Laboratory for Antiviral and Antimicrobial-Resistant Bacteria Therapeutics Research, the Research Center for the Development of Therapeutic Drugs for Serious Infectious Diseases in Shaanxi Province’s Universities and Colleges, and the Xi’an International Science and Technology Cooperation Base for Anti-Infective Drug Research and Development. His research focuses on medicinal chemistry and translational drug development, including small-molecule antivirals and antibacterials, inhibitors, PROTACs, and antibody-drug conjugates. His work also includes mechanism studies, veterinary drugs, bioequivalence evaluation, natural product modification, and the modernization of classical Chinese medicine through process optimization and quality standards. Dr. Lei Tian is a Lecturer at the School of Biological and Pharmaceutical Sciences, Shaanxi University of Science and Technology. She is affiliated with the Engineering Research Center of Major Infectious Disease Therapeutics at Universities of Shaanxi Province and the Xi’an Key Laboratory of Antiviral and Antimicrobial-Resistant Bacteria Therapeutics Research. Her research focuses on medicinal chemistry and anti-infective drug discovery, including targeted protein degradation strategies for pathogenic microorganisms and the development of therapeutics against coronaviruses and multidrug-resistant bacteria. Her work also includes the discovery and optimization of bioactive molecules through chemical synthesis, biological evaluation, pharmacological characterization, mechanism-of-action studies, and preclinical drug development.

• Part I: Antiviral Drug Discovery1. Exploring Viral and Host Targets for Antiviral Drug Discovery2. COVID-19 Challenges and its Therapeutics3. From Lab to Clinic: The Evolution of Reverse Transcriptase Inhibitors in HIV Treatment4. Targeting Hepatitis C Virus Polymerase: Non-Nucleoside Inhibitors (NNIs) and Drug Resistance5. Challenges, Progress, and Prospects of Drug Discovery to Treat Chronic Hepatitis B (CHB) Infection6. Discovery and Development of Antiviral Therapies for Influenza Virus Infections7. Medicinal Chemistry Strategies for the Discovery and Development of Anti-Herpesvirus Drugs8. Opportunities and Challenges in Targeted Protein Degradation for Antiviral Drug DiscoveryPart II: Antibacterial Drug Discovery9. Molecular Mechanisms of Antibiotic Resistance10. Overview of the Antibiotics Approved in the Last Two Decades: Retrospect and Prospect11. Antibiotic Resistance Breakers: Current Approaches and Future Directions12. Innovative Approaches in Developing Antimicrobial Peptides for Drug-Resistant Bacterial Infections13. The Potential of Antibody-Antibiotic Conjugates in Combatting Bacterial Diseases14. Phage Therapy: Current Advancements and Future Prospects in Combating Antimicrobial ResistancePart III: Drug Discovery for Miscellaneous Pathogens15. Antifungal Drug Resistance: Current Mechanisms and Future Directions16. Challenges, Unmet Clinical Needs, and Novel Approaches in the Discovery of Antifungal Drugs17. Drug Discovery against Mycobacteria: The Success and Challenges18. Future of Drug Development for the Treatment of Mycoplasma Infections19. Antimalarial Drug Discovery: From Novel Molecules to Clinical DevelopmentPart IV: Next-Generation Antimicrobial Strategies20. Computational Approaches in Antimicrobial Drug Discovery21. Multi-Omics Approaches for Antimicrobial Drug Discovery22. Nanomedicine as a Next-Generation Antimicrobial Therapy: New Frontiers in Fighting Microbial Infections23. Drug Repurposing: Innovative Antimicrobial Strategies to Combat Resistance24. Drug Combinations: A Strategy to Extend the Life of Antimicrobials25. Ethical Imperatives in Combating Antimicrobial Resistance: A Global Perspective